NasdaqGM - Nasdaq Real Time Price USD

BioAtla, Inc. (BCAB)

Compare

0.5316

-0.0284

(-5.07%)

At close: January 10 at 4:00:02 PM EST

0.5500

+0.02

+(3.46%)

After hours: January 10 at 7:21:03 PM EST

BioAtla (BCAB) Upgraded to Buy: Here's What You Should Know

BioAtla (BCAB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks 9 days ago

BCAB
-5.07%
BioAtla, Inc. Announces Registered Direct Offering to Advance Two Mid-Stage Clinical Programs to Key Inflection Points

SAN DIEGO, Dec. 20, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company (“BioAtla” or the “Company”) focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it has entered into definitive agreements with certain institutional investors for the issuance and sale of 9,679,158 shares of its common stock in a registered direct offering. Each share of common stock o

GlobeNewswire 22 days ago

BCAB
-5.07%
Insiders Give Up US$66k As BioAtla Stock Drops To US$1.31

The recent price decline of 19% in BioAtla, Inc.'s ( NASDAQ:BCAB ) stock may have disappointed insiders who bought...

Simply Wall St. 24 days ago

BCAB
-5.07%
BioAtla Presented Data Characterizing Mutated KRAS Genotype and Clinical Outcomes in Patients with Advanced NSCLC Treated with Mecbotamab Vedotin (Mec-V), a CAB-AXL-ADC, at the IASLC 2024 Hot Topic in Basic & Translational Science Meeting

Improved median overall survival (OS) for Mec-V treated patients with treatment-refractory non-small cell lung cancer (NSCLC) expressing mutated KRAS (mKRAS) as compared to Mec-V treated patient with treatment-refractory NSCLC expressing wild-type KRAS (wtKRAS) One-year OS was 58% for patients with NSCLC expressing mKRAS versus 23% for wtKRAS Mec-V antitumor activity observed across 9 different mKRAS variants Strong association of AXL expression by mKRAS NSCLC confirmed SAN DIEGO, Dec. 16, 2024

GlobeNewswire 27 days ago

BCAB
-5.07%
BioAtla Announces Upcoming Poster Presentation at the IASLC 2024 Hot Topic in Basic & Translational Science Meeting

SAN DIEGO, Dec. 10, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced a poster presentation at the upcoming International Association for the Study of Lung Cancer (IASLC) 2024 Hot Topic in Basic & Translational Science Meeting to be held in Washington, DC from December 13–15, 2024. Presentation Details: Title

GlobeNewswire last month

BCAB
-5.07%
BioAtla Inc (BCAB) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges

BioAtla Inc (BCAB) reports promising clinical trial results and strategic FDA feedback, despite a significant cash decrease and ongoing financial uncertainties.

GuruFocus.com 2 months ago

BCAB
-5.07%
3 Promising US Penny Stocks With At Least $90M Market Cap

On November 7, 2024, U.S. markets continued their upward trajectory following a post-election rally, with the S&P 500 and Nasdaq reaching record highs as the Federal Reserve announced a rate cut. In such buoyant market conditions, investors often look beyond established giants to explore opportunities in lesser-known areas like penny stocks. Although the term "penny stocks" may seem outdated, these smaller or newer companies still offer potential for growth when backed by strong financials.

Simply Wall St. 2 months ago

CNDT

BCAB
-5.07%
III
BioAtla Reports Third Quarter 2024 Financial Results and Highlights Recent Progress

Ozuriftamab vedotin (CAB-ROR2-ADC) Phase 2 trial in squamous cell carcinoma of the head and neck (SCCHN) continues to demonstrate durable clinical responses and median overall survival (OS) of approximately 9 months (ongoing) in a heavily pretreated population; actionable feedback received from the U.S. Food and Drug Administration (the “FDA”) regarding our proposed pivotal trial in second-line (2L) plus SCCHNEvalstotug (CAB-CTLA-4) in combination with PD-1 demonstrates tumor reduction in all ei

GlobeNewswire 2 months ago

BCAB
-5.07%
BioAtla to Announce Third Quarter 2024 Financial Results and Provide Business Highlights on November 7, 2024

SAN DIEGO, Oct. 31, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it plans to host a conference call and webcast on Thursday, November 7, 2024 at 4:30 p.m. ET to discuss its financial results for the third quarter ended September 30, 2024 and provide business highlights. Conference Call and Webcast I

GlobeNewswire 2 months ago

BCAB
-5.07%
BioAtla, Inc. (NASDAQ:BCAB) has caught the attention of institutional investors who hold a sizeable 39% stake

Key Insights Given the large stake in the stock by institutions, BioAtla's stock price might be vulnerable to their...

Simply Wall St. 2 months ago

BCAB
-5.07%
BioAtla, Inc. (BCAB): Among Michael Burry’s Top 10 Stock Picks Heading Into 2025

We recently compiled a list of the Michael Burry’s Top 10 Stock Picks Heading into 2025. In this article, we are going to take a look at where BioAtla, Inc. (NASDAQ:BCAB) stands against Michael Burry’s other stock picks. Established in May 2013, Scion Asset Management is a renowned and well-regarded California-based hedge fund founded by Michael […]

Insider Monkey 2 months ago

BCAB
-5.07%
^HSI
BioAtla Inc (BCAB) Q2 2024 Earnings Call Highlights: Strategic Progress Amid Financial Challenges

BioAtla Inc (BCAB) reports promising clinical advancements and strategic partnerships despite financial hurdles in Q2 2024.

GuruFocus.com 3 months ago

BCAB
-5.07%
BioAtla Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting

SAN DIEGO, Oct. 04, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced a poster presentation at the upcoming 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting, being held from November 8–10, 2024 at the George R. Brown Convention Center in Houston, TX. Presentation Details: Title: Updated results

GlobeNewswire 3 months ago

BCAB
-5.07%
BioAtla Announces Upcoming Oral Presentation at the Society for Melanoma Research 21st International Congress

SAN DIEGO, Oct. 01, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced acceptance of an abstract for oral presentation at the upcoming Society for Melanoma Research 21st International Congress (SMR), being held from October 10–13, 2024, in New Orleans, LA. Oral Presentation Details: Abstract title:Evalstotug (

GlobeNewswire 3 months ago

BCAB
-5.07%
BioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody

Context to obtain exclusive development and commercialization rights to BA3362 BioAtla to receive $15.0 million in upfront and near-term milestones, and further potential clinical, regulatory and commercial milestones of up to $118.5 million, plus royalties on net sales Context anticipated IND filing for BA3362 in mid-2026 SAN DIEGO and PHILADELPHIA, Sept. 23, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (“BioAtla”) (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the developme

GlobeNewswire 3 months ago

BCAB
-5.07%
CNTX
BioAtla Presented Phase 2 Ozuriftamab Vedotin Clinical Trial Data Demonstrating Meaningful Antitumor Activity with Manageable Tolerability among Heavily Pretreated Patients with Squamous Cell Carcinoma of the Head and Neck (SCCHN) at the 2024 European Society for Medical Oncology (ESMO) Annual Meeting

An ongoing complete response (CR) with an overall response rate (ORR) of 32% achieved across two dosing regimens Underscores ozuriftamab vedotin’s activity in a high unmet need SCCHN patient population The conditionally binding ADC targeting ROR2 was notably well tolerated The Company intends to meet with the FDA to discuss a SCCHN potential registrational trial in 2H 2024 SAN DIEGO, Sept. 16, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company fo

GlobeNewswire 3 months ago

BCAB
-5.07%
BioAtla Announces Upcoming Poster Presentation at the 2024 European Society for Medical Oncology (ESMO) Annual Meeting

SAN DIEGO, Sept. 09, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced a poster presentation at the upcoming 2024 European Society for Medical Oncology (ESMO) Annual Meeting to be held in Barcelona, Spain from September 13–17, 2024. Presentation Details: Title:Phase 2 trial of ozuriftamab vedotin (BA3021), a

GlobeNewswire 4 months ago

BCAB
-5.07%
Companies Like BioAtla (NASDAQ:BCAB) Could Be Quite Risky

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

Simply Wall St. 4 months ago

BCAB
-5.07%
BioAtla to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

SAN DIEGO, Aug. 28, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that the Company’s management will provide a corporate update at the H.C. Wainwright 26th Annual Global Investment Conference, to be held September 9-11, 2024. Format: Fireside chatDate/Time: Pre-recorded presentation available on-demand Mo

GlobeNewswire 4 months ago

BCAB
-5.07%
Bioatla Reports Second Quarter 2024 Financial Results and Highlights Recent Progress

Ozuriftamab vedotin (CAB-ROR2-ADC) granted Fast Track Designation by FDA in squamous cell carcinoma of the head and neck (SCCHN); anticipate FDA meeting for SCCHN potential registrational trial in 2H 2024Evalstotug (CAB-CTLA-4 antibody) demonstrated a similar low incidence and severity of immune-related adverse events across both Phase 1 and 2 studies; Phase 2 combination with pembrolizumab study continues to enroll and on track for initial data readout in 2H 2024Mecbotamab vedotin (CAB-AXL-ADC)

GlobeNewswire 5 months ago

BCAB
-5.07%

Performance Overview

Return	BCAB	S&P 500
YTD	-9.90%	-1.35%
1-Year	-79.15%	+22.51%
3-Year	-96.70%	+24.59%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

BioAtla, Inc. (BCAB)

BioAtla (BCAB) Upgraded to Buy: Here's What You Should Know

BioAtla, Inc. Announces Registered Direct Offering to Advance Two Mid-Stage Clinical Programs to Key Inflection Points

Insiders Give Up US$66k As BioAtla Stock Drops To US$1.31

BioAtla Presented Data Characterizing Mutated KRAS Genotype and Clinical Outcomes in Patients with Advanced NSCLC Treated with Mecbotamab Vedotin (Mec-V), a CAB-AXL-ADC, at the IASLC 2024 Hot Topic in Basic & Translational Science Meeting

BioAtla Announces Upcoming Poster Presentation at the IASLC 2024 Hot Topic in Basic & Translational Science Meeting

BioAtla Inc (BCAB) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges

3 Promising US Penny Stocks With At Least $90M Market Cap

BioAtla Reports Third Quarter 2024 Financial Results and Highlights Recent Progress

BioAtla to Announce Third Quarter 2024 Financial Results and Provide Business Highlights on November 7, 2024

BioAtla, Inc. (NASDAQ:BCAB) has caught the attention of institutional investors who hold a sizeable 39% stake

BioAtla, Inc. (BCAB): Among Michael Burry’s Top 10 Stock Picks Heading Into 2025

BioAtla Inc (BCAB) Q2 2024 Earnings Call Highlights: Strategic Progress Amid Financial Challenges

BioAtla Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting

BioAtla Announces Upcoming Oral Presentation at the Society for Melanoma Research 21st International Congress

BioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody

BioAtla Announces Upcoming Poster Presentation at the 2024 European Society for Medical Oncology (ESMO) Annual Meeting

Companies Like BioAtla (NASDAQ:BCAB) Could Be Quite Risky

BioAtla to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Bioatla Reports Second Quarter 2024 Financial Results and Highlights Recent Progress

Performance Overview